|
As global bio-pharma adjusts to evolving pricing pressures, shifting trade policies, and venture headwinds, the R&D playbook is being rewritten.
Join us for an exclusive o2h ChaiTime Webinar on topic: Trump’s MFN Drug Pricing is rewiring traditional R&D models.
🗓️ Friday, 11th July 2025
🕒 3:00 PM – 4:00 PM BST
💻 Zoom
|
|
|
We’ve got some familiar names joining the conversation, alongside our Co-founder Sunil Shah, who will be chairing the session.
■ Hilary Schultz, Founder & CEO, Persephoni BioPartners
A bold voice in biotech innovation, Hilary is driving change in early discovery by backing ventures that challenge convention. With deep insight into venture-building and investor strategy, she brings both entrepreneurial vision and investment acumen to the MFN discussion.
■ Shreefal Mehta, Member, Research and Entrepreneurial Advisory Committee, Department of Biotechnology, Government of India (BIRAC)
With over 25 years of experience across biotech and energy, Shreefal brings unique insight from both entrepreneurial and policy spheres. In his advisory role with BIRAC, he offers a rare dual lens, understanding global funding pressures while championing innovation-led ecosystems.
|
|
|
Why Attend?
- Gain insights into whether the MFN policy is purely economic or a strategic reset reshaping where and how we innovate.
- How are funding strategies and investor expectations evolving in today’s unpredictable pricing landscape?
- What does MFN mean for emerging biotechs, spinouts, and their business development playbooks?
|
|
Copyright © 2025 o2h group, All rights reserved.
You are connected with o2h discovery with regards to chemistry and biology services and related.
Our mailing address is:
o2h group
The Mill Scitech Park, Hauxton House
Mill Lane, Hauxton
Cambridge, Cambridgeshire CB22 5HX
United Kingdom
Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.
|
|
|
|
|
